🇺🇸 FDA
Patent

US 8273724

Melanoma antigens and their use in diagnostic and therapeutic methods

granted A61KA61K2239/31A61K2239/38

Quick answer

US patent 8273724 (Melanoma antigens and their use in diagnostic and therapeutic methods) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Sep 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K2239/31, A61K2239/38, A61K2239/57, A61K38/00